![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
5MB |
![[thumbnail of Supplementary Information incl. Source Data]](https://edoc.mdc-berlin.de/style/images/fileicons/other.png) |
Other (Supplementary Information incl. Source Data)
20MB |
| Item Type: | Article |
|---|---|
| Title: | Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity |
| Creators: |
Gilioli, Diego, Fusco, Simona, Tavella, Teresa, Volpari, Tatiana, Santoro, Antonella, Schönlein, Martin, Giannetti, Kety, Carsana, Edoardo, Gualandi, Nicolò, Noberini, Roberta, Brombin, Chiara, Russo, Salvatore, Feola, Sara, Giannoula, Yvonne, Branca, Rui M M, Lehtiö, Janne, Sikanen, Tiina M, Haapala, Markus, Passerini, Laura, Andrisani, Angela, Farina, Giacomo, Zangari, Alessia, Conti, Anastasia, Della Volpe, Lucrezia, Barcella, Matteo, Beretta, Stefano, Aletti, Federico Mario, Carrabba, Matteo Giovanni, Gregori, Silvia, Bonini, Chiara, Merelli, Ivan, Ciceri, Fabio, Cerullo, Vincenzo, Bonaldi, Tiziana, Vago, Luca, Schmitt, Clemens A.  ORCID: https://orcid.org/0000-0002-4731-2226 and Di Micco, Raffaella
|
| Abstract: | Chemotherapy resistance and disease relapse are major determinants of treatment failure in acute myeloid leukemia (AML). Therapy-induced senescence (TIS) is one outcome of chemotherapy, but its immunological consequences in AML remain unclear. Here we show that ex vivo chemotherapy induces senescence in a subset of therapy-naïve AML samples. TIS is marked by elevated interferon signaling, upregulation of human leukocyte antigen (HLA) class I and II molecules, and increased presentation of leukemia- and senescence-associated peptides, conferring AML cells antigen-presenting cell-like features. These changes enhance autologous CD4(+) and CD8(+) T cell responses against AML, both ex vivo and in patient-derived xenograft models. TIS also restores AML sensitivity to immune checkpoint blockade therapy. Mechanistically, we identify reduced Polycomb Repressive Complex 2 (PRC2) activity as central to TIS induction and its immunogenicity. PRC2 inhibition reactivates senescence-related genes and HLA expression in non-senescent AML cells, enabling T cell activation. These findings uncover a senescence-driven immune mechanism with potential to improve therapy outcomes in AML. |
| Keywords: | Acute Myeloid Leukemia, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cellular Senescence, Enhancer of Zeste Homolog 2 Protein, Lymphocyte Activation, Polycomb Repressive Complex 2, Tumor Cell Line, Xenograft Model Antitumor Assays, Animals, Mice |
| Source: | Nature Communications |
| ISSN: | 2041-1723 |
| Publisher: | Nature Publishing Group |
| Volume: | 17 |
| Number: | 1 |
| Page Range: | 9151 |
| Date: | 4 September 2026 |
| Official Publication: | https://doi.org/10.1038/s41467-026-76853-1 |
| PubMed: | View item in PubMed |
| Related to: |
Repository Staff Only: item control page
